Spots Global Cancer Trial Database for angiosarcoma
Every month we try and update this database with for angiosarcoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study to Learn About the Study Medicine (Called Ontorpacept or TTI-621) Given Alone and in Combination With Doxorubicin in People With Leiomyosarcoma | NCT04996004 | Leiomyosarcoma | Ontorpacept (TT... Doxorubicin | 18 Years - | Pfizer | |
| I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer | NCT01042379 | Breast Neoplasm... Breast Cancer Breast Tumors Angiosarcoma TNBC - Triple-N... HER2-positive B... HER2-negative B... Hormone Recepto... Hormone Recepto... Early-stage Bre... Locally Advance... | Standard Therap... AMG 386 with or... AMG 479 (Ganitu... MK-2206 with or... AMG 386 and Tra... T-DM1 and Pertu... Pertuzumab and ... Ganetespib ABT-888 Neratinib PLX3397 Pembrolizumab -... Talazoparib plu... Patritumab and ... Pembrolizumab -... SGN-LIV1A Durvalumab plus... SD-101 + Pembro... Tucatinib plus ... Cemiplimab Cemiplimab plus... Trilaciclib wit... SYD985 ([vic-]t... Oral Paclitaxel... Oral Paclitaxel... Amcenestrant Amcenestrant + ... Amcenestrant + ... ARX788 ARX788 + Cemipl... VV1 + Cemiplima... Datopotamab der... Datopotamab der... Zanidatamab Lasofoxifene Z-endoxifen ARV-471 ARV-471 + Letro... | 18 Years - | QuantumLeap Healthcare Collaborative | |
| Evaluation of Votrient in Angiosarcoma | NCT02212015 | Angiosarcoma | Pazopanib + Pac... | 18 Years - | Heidelberg University | |
| MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma | NCT06277154 | Leiomyosarcoma Liposarcoma Synovial Sarcom... Angiosarcoma Undifferentiate... Epithelioid Sar... Malignant Perip... Fibrosarcoma Pleomorphic Rha... Endometrial Str... Desmoplastic Sm... | MASCT-I Doxorubicin Ifosfamide | 18 Years - 70 Years | HRYZ Biotech Co. | |
| Propranolol and Pembrolizumab in Advanced Soft Tissue Sarcoma Patients | NCT05961761 | Soft Tissue Sar... Angiosarcoma Undifferentiate... | Propranolol Pembrolizumab | 18 Years - | Herlev and Gentofte Hospital | |
| Evaluation of Lipiodol® Ultra Fluid in Association With Surgical Glues During Vascular Embolization. | NCT02625389 | Congenital Hema... Hemangioendothe... Angiosarcoma Arteriovenous M... | Lipiodol® Ultra... | 18 Years - | Guerbet | |
| A Study to Learn About the Study Medicine (Called Ontorpacept or TTI-621) Given Alone and in Combination With Doxorubicin in People With Leiomyosarcoma | NCT04996004 | Leiomyosarcoma | Ontorpacept (TT... Doxorubicin | 18 Years - | Pfizer | |
| Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas | NCT04055220 | Bone Sarcoma Osteosarcoma Ewing Sarcoma Chondrosarcoma Undifferentiate... Leiomyosarcoma Angiosarcoma | Treatment by Re... Treatment by Pl... | 12 Years - | Centre Leon Berard | |
| Cytological Diagnosis of Hepatic Angiosarcoma and Its Histopathologic Correlation | NCT03025438 | Hepatic Angiosa... | 20 Years - 100 Years | National Taiwan University Hospital | ||
| Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma | NCT05799612 | Angiosarcoma | Paclitaxel mRNA plus Lysat... PEGYLATED-INTER... Filgrastim | 18 Years - | M.D. Anderson Cancer Center | |
| Evaluation of Lipiodol® Ultra Fluid in Association With Surgical Glues During Vascular Embolization. | NCT02625389 | Congenital Hema... Hemangioendothe... Angiosarcoma Arteriovenous M... | Lipiodol® Ultra... | 18 Years - | Guerbet | |
| A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas | NCT04906876 | Sarcoma Soft Tissue Sar... Metastatic Sarc... Undifferentiate... Myxofibrosarcom... Leiomyosarcoma Liposarcoma Angiosarcoma Synovial Sarcom... Rhabdomyosarcom... Spindle Cell Sa... High Grade Sarc... Bone Sarcoma | Gemcitabine Docetaxel 9-ING-41 | 10 Years - | Brown University | |
| Cemiplimab for Secondary Angiosarcomas | NCT04873375 | Secondary Angio... Locally Advance... Metastasis | Cemiplimab | 18 Years - | Radboud University Medical Center | |
| Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma | NCT05116800 | Soft Tissue Sar... Undifferentiate... Myxofibrosarcom... Leiomyosarcoma Liposarcoma Angiosarcoma Synovial Sarcom... Rhabdomyosarcom... Spindle Cell Sa... High Grade Sarc... Bone Sarcoma Osteosarcoma Ewing Sarcoma o... | Gemcitabine 9-ING-41 Docetaxel | 10 Years - | Brown University | |
| Evaluation of Votrient in Angiosarcoma | NCT02212015 | Angiosarcoma | Pazopanib + Pac... | 18 Years - | Heidelberg University | |
| Cemiplimab for Secondary Angiosarcomas | NCT04873375 | Secondary Angio... Locally Advance... Metastasis | Cemiplimab | 18 Years - | Radboud University Medical Center | |
| Boron Neutron Capture Therapy Using CICS-1 and SPM-011 for Malignant Melanoma and Angiosarcoma | NCT04293289 | Malignant Melan... Angiosarcoma | CICS-1 (investi... | 20 Years - 85 Years | Cancer Intelligence Care Systems, Inc. | |
| Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | NCT02834013 | Acinar Cell Car... Adenoid Cystic ... Adrenal Cortica... Adrenal Gland P... Anal Canal Neur... Anal Canal Undi... Angiosarcoma Apocrine Neopla... Appendix Mucino... Bartholin Gland... Basal Cell Carc... Bladder Adenoca... Breast Metaplas... Cervical Adenoc... Cholangiocarcin... Chordoma Colorectal Squa... Desmoid Fibroma... Endometrial Tra... Endometrioid Ad... Esophageal Neur... Esophageal Undi... Extrahepatic Bi... Extramammary Pa... Fallopian Tube ... Fallopian Tube ... Fibromyxoid Tum... Gallbladder Car... Gastric Neuroen... Gastric Squamou... Gastric Undiffe... Gastrointestina... Gestational Tro... Giant Cell Carc... Human Papilloma... Intestinal Neur... Intrahepatic Ch... Lung Neuroendoc... Lung Sarcomatoi... Major Salivary ... Malignant Odont... Malignant Perip... Malignant Solid... Malignant Testi... Metastatic Mali... Metastatic Pitu... Minimally Invas... Mixed Mesoderma... Mucinous Adenoc... Mucinous Cystad... Nasal Cavity Ad... Nasal Cavity Ca... Nasopharyngeal ... Nasopharyngeal ... Nasopharyngeal ... Oral Cavity Car... Oropharyngeal U... Ovarian Adenoca... Ovarian Germ Ce... Ovarian Mucinou... Ovarian Squamou... Ovarian Transit... Pancreatic Acin... Pancreatic Neur... Paraganglioma Paranasal Sinus... Paranasal Sinus... Parathyroid Gla... PEComa Penile Squamous... Peritoneal Meso... Placental Chori... Primary Periton... Pseudomyxoma Pe... Rare Disorder Scrotal Squamou... Seminal Vesicle... Seminoma Serous Cystaden... Small Intestina... Small Intestina... Spindle Cell Ne... Teratoma With S... Testicular Non-... Thyroid Gland C... Tracheal Carcin... Transitional Ce... Ureter Adenocar... Ureter Squamous... Urethral Adenoc... Urethral Squamo... Vaginal Adenoca... Vaginal Squamou... Vulvar Carcinom... | Biospecimen Col... Computed Tomogr... Echocardiograph... Ipilimumab Magnetic Resona... Nivolumab | 18 Years - | National Cancer Institute (NCI) | |
| Dose-Finding of Propranolol in Combination With Metronomic Fixed Oral Cyclophosphamide Based on Bivariate Efficacy-tolerability Outcome in Patients With Locally Advanced or Metastatic Angiosarcoma: A Collaborative and Innovative Phase I-II Sequential Trial by the French Sarcoma Group (GSF/GETO) | NCT02732678 | Angiosarcoma | PROPRANOLOL | 15 Years - | Assistance Publique Hopitaux De Marseille | |
| Efficacity of Weekly Paclitaxel in Association or Not With Bevacizumab in Metastatic or Locally Advanced Angiosarcomas | NCT01303497 | Angiosarcoma | Paclitaxel Bevacizumab | 18 Years - | Centre Oscar Lambret | |
| MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma | NCT06277154 | Leiomyosarcoma Liposarcoma Synovial Sarcom... Angiosarcoma Undifferentiate... Epithelioid Sar... Malignant Perip... Fibrosarcoma Pleomorphic Rha... Endometrial Str... Desmoplastic Sm... | MASCT-I Doxorubicin Ifosfamide | 18 Years - 70 Years | HRYZ Biotech Co. | |
| Cytological Diagnosis of Hepatic Angiosarcoma and Its Histopathologic Correlation | NCT03025438 | Hepatic Angiosa... | 20 Years - 100 Years | National Taiwan University Hospital | ||
| Study of T-VEC in Locally Advanced Cutaneous Angiosarcoma | NCT03921073 | Angiosarcoma of... | T-VEC | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE) | NCT03331250 | Angiosarcoma Epithelioid Hem... | Eribulin | 18 Years - | Massachusetts General Hospital | |
| Trial of TRC105 and Pazopanib Versus Pazopanib Alone in Patients With Advanced Angiosarcoma | NCT02979899 | Advanced Angios... | TRC105 Votrient | 12 Years - | Tracon Pharmaceuticals Inc. | |
| Evaluation of Lipiodol® Ultra Fluid in Association With Surgical Glues During Vascular Embolization. | NCT02625389 | Congenital Hema... Hemangioendothe... Angiosarcoma Arteriovenous M... | Lipiodol® Ultra... | 18 Years - | Guerbet | |
| Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE) | NCT03331250 | Angiosarcoma Epithelioid Hem... | Eribulin | 18 Years - | Massachusetts General Hospital | |
| Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas | NCT04055220 | Bone Sarcoma Osteosarcoma Ewing Sarcoma Chondrosarcoma Undifferentiate... Leiomyosarcoma Angiosarcoma | Treatment by Re... Treatment by Pl... | 12 Years - | Centre Leon Berard | |
| Identification, Molecular Epidemiology Angiosarcoma of the Liver France | NCT01786889 | Angiosarcoma | blood and urine Questionnaire Telephone inter... | - | Centre Oscar Lambret | |
| Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma | NCT02584309 | Sarcoma, Soft T... Soft Tissue Sar... Undifferentiate... Leiomyosarcoma Liposarcoma Synovial Sarcom... Myxofibrosarcom... Angiosarcoma Fibrosarcoma Malignant Perip... Epithelioid Sar... | Dexrazoxane Doxorubicin | 18 Years - | Washington University School of Medicine | |
| Identification, Molecular Epidemiology Angiosarcoma of the Liver France | NCT01786889 | Angiosarcoma | blood and urine Questionnaire Telephone inter... | - | Centre Oscar Lambret | |
| Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes | NCT00887809 | Sarcoma Leiomyosarcoma Malignant Fibro... Histiocytoma Angiosarcoma | gemcitabine docetaxel bevacizumab | 18 Years - 75 Years | Memorial Sloan Kettering Cancer Center | |
| A Study to Learn About the Study Medicine (Called Ontorpacept or TTI-621) Given Alone and in Combination With Doxorubicin in People With Leiomyosarcoma | NCT04996004 | Leiomyosarcoma | Ontorpacept (TT... Doxorubicin | 18 Years - | Pfizer | |
| Prospective Observational Study of Localized Angiosarcoma of Any Site: ProStars | NCT06375941 | Angiosarcoma | Observational | - | Italian Sarcoma Group | |
| Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE) | NCT03331250 | Angiosarcoma Epithelioid Hem... | Eribulin | 18 Years - | Massachusetts General Hospital | |
| Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer | NCT03860272 | Advanced Cancer Angiosarcoma Colorectal Canc... Endometrial Can... Fibrolamellar C... Non-small-cell ... Ovarian Cancer Prostate Cancer | Botensilimab Balstilimab | 18 Years - | Agenus Inc. | |
| AGEN2034 & AGEN1884 in Patients With Recurrent, Inoperable Angiosarcoma | NCT04607200 | Angiosarcoma | AGEN2034 AGEN1884 | 18 Years - | Agenus Inc. | |
| Boron Neutron Capture Therapy Using CICS-1 and SPM-011 for Malignant Melanoma and Angiosarcoma | NCT04293289 | Malignant Melan... Angiosarcoma | CICS-1 (investi... | 20 Years - 85 Years | Cancer Intelligence Care Systems, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
